Related Experiment Video
Updated: Aug 30, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
New long-acting androgens
1Department of Endocrinology, Section of Andrology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. ljg.gooren@vumc.nl
Abstract:
Testosterone substitution treatment aims to replace physiological actions of endogenous testosterone by steadily maintaining physiological blood levels of testosterone. The underlying conditions rendering androgen replacement necessary are usually irreversible. The consequence is that almost life-long androgen replacement is required. Patient compliance with life-long androgen replacement depends on convenient pharmaceutical formulations ensuring continuity of androgen replacement. Therefore, they must be convenient in usage with a relative independence of medical services. In elderly man, safety of androgen replacement therapy is a concern but in younger subjects (below the age of 50 years) side effects of androgens are usually minimal. For them, long-acting testosterone preparations are well suited. Testosterone implants generate, depending on the dose of implants, 3-6 months of normal plasma testosterone. This method requires minor surgery. Injectable testosterone undecanoate maintains plasma testosterone in the normal range for 12 weeks.
Related Concept Videos
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
